Search

Your search keyword '"Siddiqui, Mustaqeem A."' showing total 113 results

Search Constraints

Start Over You searched for: Author "Siddiqui, Mustaqeem A." Remove constraint Author: "Siddiqui, Mustaqeem A." Language english Remove constraint Language: english
113 results on '"Siddiqui, Mustaqeem A."'

Search Results

1. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

2. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

3. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients

5. Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region.

6. Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)

7. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities

8. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy

9. A simple additive staging system for newly diagnosed multiple myeloma

11. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy

12. Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients

14. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients

15. Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients

16. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response

19. Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma

24. 47 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma

27. Prognostic significance of acquired 1q22 gain in multiple myeloma.

30. P-209: Deepening responses post upfront ASCT in newly diagnosed multiple myeloma in the era of novel agent induction therapy

32. Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide.

34. Colon perforation in multiple myeloma patients – A complication of high‐dose steroid treatment.

35. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio.

36. 230 - Outpatient Practice Pattern and Clinical Outcome for Axicabtagene Ciloleucel in Patients with Aggressive Lymphoma

38. Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis

39. Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients

40. Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM)

41. Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)

42. Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM)

43. The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma

44. MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients

45. A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders

46. Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma

47. Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis

48. Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

49. Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition

50. Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States.

Catalog

Books, media, physical & digital resources